Telix Pharmaceuticals director reports shareholdings
Telix Pharmaceuticals Ltd director Nelson Mark Alexander has filed an initial Form 3 reporting his existing shareholdings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Telix Pharmaceuticals Ltd director Nelson Mark Alexander has filed an initial Form 3 reporting his existing shareholdings. The filing shows indirect beneficial ownership of 3,628,750 Ordinary Shares held through MAN Holdings Pty Ltd, acting as trustee for the Nelson Hybrid Trust, of which he is a director and shareholder. This filing records his current position rather than any new share purchase or sale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- F1. MAN Holdings Pty Ltd, as Trustee for the Nelson Hybrid Trust, of which Mr. Nelson is a director and shareholder.
Key Figures
Key Terms
Form 3 regulatory
indirect ownership financial
trustee financial
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Telix Pharmaceuticals (TLX) director Nelson Mark Alexander report on this Form 3?
Does this Telix Pharmaceuticals (TLX) Form 3 show any recent insider buying or selling?
What type of ownership is reported by Telix Pharmaceuticals (TLX) director Nelson Mark Alexander?
Why is a Form 3 filing important for Telix Pharmaceuticals (TLX) investors?
AI-generated analysis. How Rhea-AI works. Not financial advice.